David J Feola

List of Publications by Year
in descending order

40 papers	1,563 citations	471061 17 h-index	315357 38 g-index
41 all docs	41 docs citations	41 times ranked	2283 citing authors

#	Article	IF	Citations
1	Lessons Learned From the COVID-19 Pandemic and the Implications for Pharmaceutical Graduate Education and Research. Advances in Medical Education, Research, and Ethics, 2022, , 324-345.	0.1	0
2	Azithromycin and Major Adverse Kidney Events in Critically Ill Patients With Sepsis-Associated Acute Kidney Injury. Shock, 2022, 57, 479-485.	1.0	2
3	Delivering macrolide antibiotics to heal a broken heart â€“ And other inflammatory conditions. Advanced Drug Delivery Reviews, 2022, 184, 114252.	6.6	5
4	1410: AZITHROMYCIN AND MAJOR ADVERSE KIDNEY EVENTS IN CRITICALLY ILL PATIENTS WITH SEPSIS-ASSOCIATED AKI. Critical Care Medicine, 2022, 50, 707-707.	0.4	0
5	Myeloid arginase-1 controls excessive inflammation and modulates T cell responses in Pseudomonas aeruginosa pneumonia. Immunobiology, 2021, 226, 152034.	0.8	3
6	Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. Frontiers in Immunology, 2021, 12, 574425.	2.2	38
7	Myeloid Arginase 1 Insufficiency Exacerbates Amyloid-Î² Associated Neurodegenerative Pathways and Glial Signatures in a Mouse Model of Alzheimerâ€™s Disease: A Targeted Transcriptome Analysis. Frontiers in Immunology, 2021, 12, 628156.	2.2	6
8	Bias of the Immune Response to Pneumocystis murina Does Not Alter the Ability of Neonatal Mice to Clear the Infection. Journal of Fungi (Basel, Switzerland), 2021, 7, 827.	1.5	1
9	Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction. Scientific Reports, 2020, 10, 16596.	1.6	10
10	Arginase 1 Insufficiency Precipitates Amyloid-Î² Deposition and Hastens Behavioral Impairment in a Mouse Model of Amyloidosis. Frontiers in Immunology, 2020, 11, 582998.	2.2	15
11	Appropriateness of Term Limits for Administrative Appointments in Pharmacy Programs. American Journal of Pharmaceutical Education, 2020, 84, 7462.	0.7	3
12	Azithromycin Polarizes Macrophages to an M2 Phenotype via Inhibition of the STAT1 and NF-ÎºB Signaling Pathways. Journal of Immunology, 2019, 203, 1021-1030.	0.4	85
13	Development of Guiding Principles for a New Era in Graduate Education. American Journal of Pharmaceutical Education, 2019, 83, 7422.	0.7	3
14	Effect of increasing meropenem MIC on the killing activity of meropenem in combination with amikacin or polymyxin B against MBL- and KPC-producing Enterobacter cloacae. Diagnostic Microbiology and Infectious Disease, 2018, 92, 262-266.	0.8	17
15	Azithromycin therapy reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction: Potential therapeutic targets in ischemic heart disease. PLoS ONE, 2018, 13, e0200474.	1.1	39
16	Effect of the meropenem MIC on the killing activity of meropenem and polymyxin B in combination against KPC-producing Klebsiella pneumoniae. Journal of Antibiotics, 2017, 70, 974-978.	1.0	8
17	Pneumocystis infection alters the activation state of pulmonary macrophages. Immunobiology, 2017, 222, 188-197.	0.8	14
18	Azithromycin drives alternative macrophage activation and improves recovery and tissue sparing in contusion spinal cord injury. Journal of Neuroinflammation, 2015, 12, 218.	3.1	76

#	Article	IF	Citations
19	B Lymphocytes Are Required during the Early Priming of CD4+ T Cells for Clearance of Pneumocystis Infection in Mice. Journal of Immunology, 2015, 195, 611-620.	0.4	36
20	Agents that increase AAM differentiation blunt RSV-mediated lung pathology. Journal of Leukocyte Biology, 2014, 96, 951-955.	1.5	12
21	Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 164-171.	0.3	31
22	Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. Journal of Thrombosis and Thrombolysis, 2013, 35, 147-154.	1.0	55
23	Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2013, 68, 840-851.	1.3	11
24	Linezolid Decreases Susceptibility to Secondary Bacterial Pneumonia Postinfluenza Infection in Mice Through its Effects on IFN-Î³. Journal of Immunology, 2013, 191, 1792-1799.	0.4	19
25	Pulmonary function outcomes in bronchopulmonary dysplasia through childhood and into adulthood: implications for primary care. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2011, 20, 128-133.	2.5	16
26	Phytosterols differentially influence ABC transporter expression, cholesterol efflux and inflammatory cytokine secretion in macrophage foam cells. Journal of Nutritional Biochemistry, 2011, 22, 777-783.	1.9	76
27	Eradication ofPseudomonas aeruginosain an adult patient with cystic fibrosis. American Journal of Health-System Pharmacy, 2011, 68, 319-322.	0.5	3
28	Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis. Pediatric Pulmonology, 2010, 45, 1145-1148.	1.0	36
29	Aerosolized vancomycin for the treatment of MRSA after lung transplantation. Respirology, 2010, 15, 184-186.	1.3	31
30	Azithromycin Alters Macrophage Phenotype and Pulmonary Compartmentalization during Lung Infection with Pseudomonas. Antimicrobial Agents and Chemotherapy, 2010, 54, 2437-2447.	1.4	81
31	Characterization of macrophage activation states in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2010, 9, 314-322.	0.3	61
32	Pathogenesis of Bronchopulmonary Dysplasia. Respiration, 2010, 79, 425-436.	1.2	73
33	Airway dehiscence after lung transplantation in a patient with cystic fibrosis. Respiratory Care, 2010, 55, 1746-50.	0.8	6
34	Mucoid Inquilinus limosus in a young adult with cystic fibrosis. Pediatric Pulmonology, 2009, 44, 619-621.	1.0	12
35	Azithromycin alters macrophage phenotype. Journal of Antimicrobial Chemotherapy, 2008, 61, 554-560.	1.3	160
36	Combination Exposure to Zidovudine plus Sulfamethoxazole-Trimethoprim Diminishes B-Lymphocyte Immune Responses to Pneumocystis murina Infection in Healthy Mice. Vaccine Journal, 2006, 13, 193-201.	3.2	4

#	Article	IF	Citations
37	Zidovudine plus sulfamethoxazoleâ€“trimethoprim adversely affects B lymphocyte maturation in bone marrow of normal mice. International Immunopharmacology, 2005, 5, 1881-1894.	1.7	4
38	Metronidazole-Induced Pancreatitis in a Patient with Recurrent Vaginal Trichomoniasis. Pharmacotherapy, 2002, 22, 1508-1510.	1.2	18
39	Polymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria. Annals of Pharmacotherapy, 1999, 33, 960-967.	0.9	492
40	Optimization and Characterization of a Liposomal Azithromycin Formulation for Alternative Macrophage Activation. Frontiers in Drug Delivery, 0, 2, .	0.4	0